Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16115695 | 0.82 | USP30 (0.42) | GRM1SLC6A7USP30 | |
| SCHEMBL26096238 | 0.81 | GRM1 (0.38) | GRM1SLC6A7USP30 | |
| SCHEMBL26096173 | 0.81 | CHRM2 (0.35) | GRM1NR1H2NR1H3SLC6A7 | |
| SCHEMBL26095232 | 0.79 | USP30 (0.31) | SLC6A7USP30 | |
| SCHEMBL20520145 | 0.77 | USP30 (0.39) | USP30 | |
| SCHEMBL14159644 | 0.76 | CHRM4 (0.33) | GRM1SLC6A7USP30 | |
| SCHEMBL21194361 | 0.76 | GRM1 (0.36) | GRM1NR1H2NR1H3SLC6A7USP30 | |
| SCHEMBL26095713 | 0.76 | NOTUM (0.37) | NR1H2NR1H3SLC6A7 | |
| SCHEMBL26094167 | 0.75 | CHRM2 (0.38) | NR1H2NR1H3 | |
| SCHEMBL29683489 | 0.75 | CKS1B (0.44) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | GRM1 3635/4885NR1H2 2330/4885NR1H3 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.